Medco Research Adenoscan
Executive Summary
Abbott will market the adenosine infusion product for use as an adjunct to cardiac imaging. Abbott previously had signed an agreement to manufacture the drug after Medco terminated its relationship with Fujisawa USA, claiming that regulatory compliance problems at Fujisawa were holding up approval. Adenoscan has been "approvable" since Dec. 13. Medco predicts that the drug will be launched "following submission of manufacturing documents and approval of Abbott's manufacturing facility by FDA"